Our Approach:
Advancing Evidence-Based Cancer Treatments that the Market Overlooks
Why We Exist
The current drug development system has evolved to advance products with commercial upside. As a result, many off-patent drugs, despite scientific evidence supporting new cancer uses, are left under-investigated and under-developed.
Reboot Rx was founded to address this market gap by identifying new uses for existing, affordable treatments that can complement the current standard of care and improve survival or quality of life. Our focus is on repurposing off-patent drugs that can be used as is, not creating new patents or products.
Our Approach
We use our AI-powered evidence synthesis platform to surface treatment opportunities supported by clinical data. Our research collaborations and clinical partnerships help ensure they are evaluated with the rigor needed for sound clinical decision-making.
Because these drugs are already approved for human use, with known safety profiles and established manufacturing, advancing a new cancer indication typically requires fewer development steps than creating a new drug from scratch. The challenge is coordination: assembling the right evidence, filling targeted gaps, and supporting the work needed for consideration in clinical practice.
Our Method
IDENTIFY
Using AI-enabled natural language processing and biomedical information extraction, we scan the global medical literature to identify relevant studies, extract key outcomes, and map evidence across cancer types and indications. These signals are synthesized and reviewed to rank candidate drugs based on the totality of available evidence and potential clinical impact.
INVESTIGATE
We further assess each opportunity using a structured evaluation framework, and where additional data are needed, we partner with researchers and health systems to fill key evidence gaps through clinical studies.
We prioritize drugs with the highest likelihood of large-scale patient impact, with a focus on early-stage cancer and improving quality of life, extending survival, slowing progression, and reducing recurrences.
How We Prioritize Opportunities:
Strength and consistency of the clinical evidence
Potential to address unmet needs in cancer care
Low Cost to Patients
Safety Profile
Stable drug supply and widespread accessibility
Feasibility for near-term clinical adoption
INFORM
We share clear, objective evidence summaries that reflect the full scope of available data, helping clinicians, researchers, and health systems understand the landscape and make well-informed decisions.
Built to Scale
Our opportunity pipeline is designed to expand as more medicines become generic and as new clinical evidence emerges. With additional collaboration and investment, Reboot Rx can increase analytical capacity and support additional research to move high-impact treatment opportunities through the evaluation process.
Working With Us
Our approach depends on strong collaborations with clinicians, research institutions, health system leaders, and philanthropic funders who share our commitment to advancing evidence-based, affordable cancer care.